Recent layoffs at the FDA have left the agency grappling with significant challenges, as key officials depart and operations face cuts. Reports indicate that the agency is planning to reduce food and drug inspections due to these layoffs, which has raised alarms about the potential for increased drug costs and compromised food safety. With senior officials from vital programs laid off and many positions in limbo, the drug industry is expressing concerns about testing delays and regulatory uncertainty. Food safety leaders and local businesses are also worried about the implications of these cuts on public health. The situation is exacerbated by ongoing discussions about funding and priorities within the agency amidst a broader federal overhaul. As the FDA navigates these turbulent changes, stakeholders are calling for clarity on how these cutbacks will influence upcoming user fee negotiations and overall safety standards.